Recent news items primarily relate to broader market and sector developments rather than Cartesian Growth Corp II specifically. The company has not announced new business combinations or operational milestones recently.

• The company’s sector and market environment include pharmaceutical revenue growth and biosimilar deals, stock buybacks by large firms, and mixed market performance in Europe and Asia, none directly related to Cartesian Growth Corp II [N1][N2][N3][N4][N5][N6][N7][N8].

The company’s focus on high-growth, transnational businesses and the experience of its management team could provide opportunities to identify attractive acquisition targets. The substantial funds held in trust provide financial resources to consummate a business combination. The multiple extensions of the business combination deadline indicate ongoing efforts to complete a transaction. If a suitable target is identified and combined, the company could transition from a blank check entity to an operating business with growth potential.

The company has not completed a business combination within the original or extended deadlines, resulting in delisting from Nasdaq and trading on OTC Pink, which may limit investor interest and liquidity. It faces substantial doubt about its ability to continue as a going concern due to liquidity constraints and lack of capital resources to fund operations and complete a business combination. The absence of operating revenues and ongoing net losses increase financial risk. Failure to complete a business combination by the current deadline could lead to liquidation and loss of shareholder value.

As a blank check company, Cartesian Growth Corp II does not currently possess a business moat. Its value proposition depends on successfully identifying and completing a business combination with a high-growth target company. The company’s management team leverages experience and networks to seek transnational businesses with potential for value creation post-combination. However, until a business combination is consummated, the company’s operations are limited to administrative and organizational activities, and it holds no competitive advantages or operating assets.

• Business Combination Completion Risk: The company has repeatedly extended its deadline to complete a business combination but has not yet consummated one. Failure to complete a business combination by August 5, 2026, or secure an extension, could result in liquidation and loss of shareholder value.
• Liquidity and Going Concern Risk: As of June 30, 2026, the company has very low liquidity with a current ratio of 0.04 and a working capital deficit. There is substantial doubt about its ability to continue as a going concern without completing a business combination or raising additional capital.
• Market Listing and Liquidity Risk: The company’s securities were delisted from Nasdaq in May 2025 and now trade on the OTC Pink market, which may reduce market visibility, liquidity, and investor interest.
• Operational Risk: The company has no operating revenues and limited operations, relying on funds held in trust and sponsor loans. Its ability to identify and complete a business combination depends on management’s execution and market conditions.

• Cartesian Growth Corp II is a blank check company (SPAC) incorporated in the Cayman Islands on October 13, 2021, formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities.
• The company focuses on seeking high-growth businesses with proven or potential transnational operations or outlooks to leverage the management team's experience and network.
• It intends to use cash from IPO net proceeds, private placement warrants, sponsor loans, share capital, or a combination thereof to effectuate its initial business combination.
• The company has not generated any operating revenues to date and has only engaged in organizational activities and IPO preparation.
• Its securities were delisted from Nasdaq on May 13, 2025, and have since traded on the OTC Pink market under symbols RENEF, REEUF, and REEWF.
• As of March 31, 2026, there were very few holders of record for its units, Class A and B ordinary shares, and warrants, with many shares held in street name.
• The company has not paid any cash dividends and does not intend to do so prior to completing its initial business combination.
• As of June 30, 2026, the company had current assets of $236,200 and current liabilities of $6,125,098, resulting in a current ratio of 0.04, indicating very low liquidity.
• The company reported a net loss of $699,615 for the quarter ended June 30, 2026.
• Basic and diluted earnings per share were $0.13 as of June 30, 2023, but no recent EPS data is available for 2026.
• The company held approximately $37.9 million in cash and marketable securities in its trust account as of December 31, 2025, intended for use in completing a business combination or redeeming public shares if unable to complete such combination.
• Operating costs for the year ended December 31, 2025, were $931,461, with net loss of $1,512,540, including changes in fair value of warrant liabilities and convertible promissory notes.
• The company has issued unsecured promissory notes to its sponsor, some convertible into warrants, to fund working capital and extension payments for the business combination deadline.
• The company has extended the deadline to complete its initial business combination multiple times, with the current deadline extended to August 5, 2026.
• There is substantial doubt about the company's ability to continue as a going concern due to liquidity constraints and the approaching deadline for completing a business combination without an approved extension plan.
• The company has no approved plan to extend the business combination deadline beyond August 5, 2026, and lacks capital resources to fund operations and complete a business combination if the deadline is not extended.
• The company uses funds outside the trust account primarily for identifying and evaluating target businesses, due diligence, travel, document review, negotiation, and directors and officers insurance premiums.
• The company pays its sponsor $10,000 per month for office space, utilities, secretarial support, and administrative services, provided by an affiliate of the sponsor.
• The company has no material litigation or governmental proceedings pending against it or its management.
• The company’s financial instruments are classified within fair value hierarchy levels, with fair value approximating carrying amounts due to short-term nature.
• The company’s deferred underwriting commission of $11.5 million is held in the trust account and will be released only upon consummation of the initial business combination.
• The company’s net tangible assets and shareholders’ deficit have been negatively impacted by accumulated losses and remeasurement of redeemable shares.
• The company’s management discusses financial condition and results of operations in SEC filings, emphasizing the uncertainty and risks related to completing a business combination.
• Recent business news items related to the company’s sector or market environment include pharmaceutical revenue growth, stock buybacks, biosimilar deals, and market performance, but none directly pertain to Cartesian Growth Corp II.